connexin 26 Lentiviral Activation Particles (h): sc-402132-LAC
- Target species: human
- 200 µl of transduction-ready, high-titer CRISPR/dCas9 Lentiviral Activation Particles
- connexin 26 Lentiviral Activation Particles (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically and efficiently upregulate gene expression via lentiviral transduction of cells
- connexin 26 Lentiviral Activation Particles (h) contain the following SAM Activation elements: a deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, an MS2-p65-HSF1 fusion protein and a target-specific 20 nt guide RNA. They also contain the blasticidin, hygromycin and puromycin resistance genes
- Upon transduction, the SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by connexin 26 Lentiviral Activation Plasmid (h) and connexin 26 Lentiviral Activation Plasmid (h2) target distinct regulatory regions of the GJB2 promoter. One or both designs may be available
- Following transfection, gene activation efficiency can be assayed by WB, IF or IHC using antibody: connexin 26 Antibody (1C6): sc-293223
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
connexin 26 Lentiviral Activation Particles (h) | sc-402132-LAC | 200 µl | $455.00 |
GJB2 encodes connexin 26, a gap junction channel protein that assembles into connexons to mediate direct intercellular exchange of ions and small metabolites, supporting electrical and metabolic coupling. Connexin 26 regulates tissue homeostasis by coordinating signaling in epithelia and sensory tissues, with consequences for cell differentiation, stress responses, and barrier function. Altered GJB2 expression or connexin 26 channel function is strongly linked to hereditary hearing loss and other disorders of epithelial physiology, making it a widely used target in models of cochlear biology and gap junction communication. In research settings, connexin 26 provides a tractable entry point to study gap junction dynamics, cellular connectivity, and transcriptional control of junctional proteins.
connexin 26 Lentiviral Activation Particles (h) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient GJB2 upregulation across a broader range of human cell types.
connexin 26 Lentiviral Activation Particles (h) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the GJB2 transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous connexin 26 expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native GJB2 genomic locus and regulatory architecture.
The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.